Mayne Pharma Group Ltd
ASX:MYX
Mayne Pharma Group Ltd
Depreciation & Amortization
Mayne Pharma Group Ltd
Depreciation & Amortization Peer Comparison
Competitive Depreciation & Amortization Analysis
Latest Figures & CAGR of Competitors
Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Mayne Pharma Group Ltd
ASX:MYX
|
Depreciation & Amortization
-AU$56.6m
|
CAGR 3-Years
7%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
Depreciation & Amortization
-AU$335.2k
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-44%
|
CAGR 10-Years
N/A
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Depreciation & Amortization
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Botanix Pharmaceuticals Ltd
ASX:BOT
|
Depreciation & Amortization
-AU$118.9k
|
CAGR 3-Years
0%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Probiotec Ltd
ASX:PBP
|
Depreciation & Amortization
-AU$6.2m
|
CAGR 3-Years
-100%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Depreciation & Amortization
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Mayne Pharma Group Ltd's Depreciation & Amortization?
Depreciation & Amortization
-56.6m
AUD
Based on the financial report for Jun 30, 2023, Mayne Pharma Group Ltd's Depreciation & Amortization amounts to -56.6m AUD.
What is Mayne Pharma Group Ltd's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 5Y
4%
Over the last year, the Depreciation & Amortization growth was -18%. The average annual Depreciation & Amortization growth rates for Mayne Pharma Group Ltd have been 7% over the past three years , 4% over the past five years .